aeggermont

Alexander Eggermont is the Director General of the Cancer Institute Gustave Roussy, Villejuif-Paris, France. He is Professor of Surgical Oncology and Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam. He holds the ‘Joseph Maisin Chair in Oncology at the Catholic University of Leuven in Belgium. In 1987 he obtained his PhD on ‘Interferon and IFN-Inducers in the Treatment of Cancer’ at the Erasmus University Rotterdam and is a former Fellow of the NCI Surgery Branch, NIH, Bethesda, USA.

His clinical specialties include melanoma, sarcoma and regional therapy techniques as well as general drug development and clinical trial methodology. He is a past Chair of the EORTC MG Group and current Chair of the Adjuvant Therapy Committee EORTC Melanoma Group. His basic research field is in tumor immunology, advanced imaging models and tumor pathophysiology.

Professor Eggermont is the author or co-author of over 600 peer-reviewed publications, book chapters and monographs. More than 30 PhD theses have originated in his clinical and basic laboratory research programs at the Erasmus University MC Rotterdam.

International functions
- European Academy of Cancer Sciences: President 2010-2013
- ECCO: Immediate past President of ECCO (the European CanCer Organization)
- EORTC: Past President of EORTC (European Organisation for Research and Treatment of Cancer), Executive Committee of the Board (1997-2009). Chairman of the Melanoma Group (1994-2000) and current Chair of the Committee on Adjuvant Treatment Strategies of the EORTC Melanoma Group
- OECI (Organization of European Cancer Institutes): President-Elect
- ASCO: Past Member of Board of Directors of ASCO. JCO Editorial Board
- AACR: Various past committee memberships Past Deputy Editor of Clinical Cancer Research
- Deutsche Krebshilfe: Chair International Jury for Comprehensive Cancer Center Program
- European Journal of Cancer: Editor-in-Chief per 01-01-2011

Key EORTC-related Publications last 5 years:
- Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
Van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van Leeuwen PA, Voit CA, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM.
J Clin Oncol. 2011 Jun 1;29(16):2206-14. Epub 2011 Apr 25.
- Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies- EORTC18991.
Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM.
J Clin Oncol. 2010 May 10;28(14):2460-6.
- Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM;
J Natl Cancer Inst. 2009 Jun 16;101(12):869-77.
- Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the EORTC Melanoma Group.
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont AM.
J Clin Oncol. 2009 Jun 20;27(18):2916-23
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTCMelanoma Group.
Lancet. 2008 Jul 12;372(9633):117-26.
- Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D; EORTC Melanoma Group.
Lancet. 2005 Oct 1;366(9492):1189-96.